[1]ZION YC,PAPPADOPULOS E,WAJNRAJCH M,et al.Rethinking fatigue in Gaucher disease[J].Orphanet J Rare Dis,2016,29(4):1-7.
|
[2]MHANNI AA,KOZENKO M,HARTLEY JN.Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease[J].Mol Genet Metab Rep,2015,29(12):13-15.
|
[3]KOPPE T,DONEDA D,SIEBERT M.The prognostic value of the serum ferritin in a southern Brazilian cohort of patients with Gaucher disease[J].Genet Mol Biol,2016,39(3):30-34.
|
[4]LINARI S.Clinical manifestations and management of Gaucher disease[J].Clin Cases Miner Bone Metab,2015,12(2):157-164.
|
[5]MANISHA B,THOMAS AB,JOEL C,et al.Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States[J].Mol Genet Metab,2016,117(2):95-103.
|
[6]SECHI A,DARDIS A,BEMBI B.Profile of eliglustat tartrate in the management of Gaucher disease[J].Ther Clin Risk Manag,2016,11(1):53-58.
|